RT Journal Article
SR Electronic
T1 Delivered dose of colistimethate sodium via 3 nebulizers; a comparison of bioassay and HPLC assay results
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P1187
VO 42
IS Suppl 57
A1 Adam Metcalf
A1 Sarah Byrne
A1 Danielle Jeffrey
A1 Ross Hatley
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P1187.abstract
AB In vitro assessment of the dose of inhaled colistimethate sodium (CMS) delivered via a nebulizer has traditionally relied on bioassay (BA). An alternative method is high performance liquid chromatography (HPLC).A custom HPLC assay for CMS has been developed; this is a reversed-phase gradient assay using a 100 x 4.6 mm, 2.6 µm solid core C18 column with UV detection. The HPLC assay was compared with BA using different nebulizers and breathing patterns. Here, results from 3 nebulizers (I-neb AAD System (I-neb), LC Sprint (LCS), LC Plus (LCP)) under 4 breathing patterns are presented. Nebulizers (n=3) were tested using a method described by Byrne et al. (1) Eluate from each filter was analyzed using both BA and HPLC assay.View this table:Table 1: Summary of mean BA and HPLC assay results (MIU) for each nebulizer/breathing pattern combination.The 2 measurement techniques were compared using a Bland-Altman plot. HPLC assay and BA results were consistent; the majority of results fell within 10% of each other (mean difference, 2.8%; limits of agreement, 14.6% to -8.9%). Advantages of the custom HPLC assay include simplicity and speed, whilst yielding results in close agreement with the standard BA.1) Byrne S, et al. ISAM 2013 abstracts. J Aerosol Med Pulm Drug Deliv.